LGC’s high-throughput PCR testing system for SARS-CoV-2 detection granted Emergency Use Authorisation

LGC’s high-throughput SARS-CoV-2 Real-Time and End-Point RT-PCR Test has been granted Emergency Use Authorisation (EUA) by the FDA. It is the highest throughput PCR testing system to be approved to date, with the capability of processing up to 35,000 tests per day.

The FDA’s authorisation enables qualified laboratories to address SARS-CoV-2 testing demands while providing significant economic advantage when compared to other technologies.

Mark Dearden, Managing Director, LGC, Biosearch Technologies, said, “This tool is a game-changer in our fight against COVID-19. It offers the gold standard of PCR testing but with economics to support routine diagnostics at scale.”
Dearden continued, “The benefits of large-scale PCR testing can’t be underestimated. We know that extensive and frequent testing is a key tool for tracking and managing the spread of the virus. Used in concert with other point-of-need testing and continued vaccine rollout, the LGC solution can enhance our ability to fight the pandemic.”

LGC’s testing system has been built to be flexible and scalable, allowing organisations to meet changing SARS-CoV-2 testing needs.

The company has been involved in the response to the COVID-19 pandemic since January 2020. It has a proven track record in supporting the scientific and healthcare community with diagnostics for public health diseases as well as public health emergencies such as influenza, H1N1 (swine flu), Zika, and Ebola.